Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE.

Gold, Ralf; Arnold, Douglas L; Bar-Or, Amit; Fox, Robert J; Kappos, Ludwig; Chen, Chongshu; Parks, Becky; Miller, Catherine

Gold, Ralf; Arnold, Douglas L; Bar-Or, Amit; Fox, Robert J; Kappos, Ludwig; Chen, Chongshu; Parks, Becky; Miller, Catherine.

Afiliação

Gold R; Department of Neurology, St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany.
Arnold DL; Montreal Neurological Institute, McGill University and NeuroRx Research, Montreal, QC, Canada.
Bar-Or A; Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Fox RJ; Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, USA.
Kappos L; Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University, Basel, Switzerland.
Chen C; Biogen, Cambridge, MA, USA.
Parks B; Biogen, Cambridge, MA, USA.
Miller C; Biogen, 225 Binney Street, Cambridge, MA 02142, USA.

Ther Adv Neurol Disord ; 13: 1756286420915005, 2020.

Article em En | MEDLINE | ID: mdl-32426039